The Lancet Gastroenterology & Hepatology

The Lancet Gastroenterology & Hepatology is a monthly medical journal published by Elsevier as part of the Lancet Group, launched in 2016 and dedicated to all aspects of gastroenterology and hepatology, with a 2025 Journal Impact Factor of 39.1《柳叶刀：胃肠病学与肝病学》（The Lancet Gastroenterology & Hepatology）是由（Elsevier）出版、隶属柳叶刀集团（Lancet Group）的医学月刊，2016 年创刊，专注于胃肠病学与肝病学的各个领域，2025 年影响因子为 39.1。

Scope

• It is an authoritative forum for key opinion leaders across medicine, government and health systems to influence clinical practice, explore global policy and inform constructive change worldwide该刊是面向医学、政府与卫生系统意见领袖的权威论坛，用以影响临床实践、探讨全球政策并推动建设性变革。
• It publishes original research, expert review, opinion and news covering international issues该刊刊载原创研究、专家综述、观点与新闻，涵盖国际性议题。
• It provides a clear, independent perspective on the clinical advances and practice-changing research shaping these specialties globally该刊就塑造全球胃肠与肝病专科的临床进展与改变实践的研究，提供清晰而独立的视角。
• Its coverage especially includes inflammatory bowel diseases其报道尤其涵盖炎症性肠病。
• Its coverage especially includes NAFLD and NASH, the steatotic liver diseases其报道尤其涵盖 NAFLD 与 NASH 等脂肪性肝病。
• Its coverage especially includes functional gastrointestinal disorders其报道尤其涵盖功能性胃肠病。
• Its coverage especially includes digestive cancers其报道尤其涵盖消化道肿瘤。
• Its coverage especially includes viral hepatitis其报道尤其涵盖病毒性肝炎。
• Each monthly issue features original clinical research, expert reviews, news, and provocative comment and opinion每期月刊均刊载原创临床研究、专家综述、新闻以及富有见地的评论与观点。

History

• The journal was launched in 2016, and its first issue appeared in September 2016 as Volume 1, Issue 1, opening with an editorial titled putting the inside out该刊于 2016 年创刊，首期于 2016 年 9 月出版，为第 1 卷第 1 期，以题为（putting the inside out）的社论开篇。^[1]
• It is one of the specialty journals created in the Lancet Group's second phase of expansion, alongside titles such as The Lancet Diabetes & Endocrinology and The Lancet Global Health该刊是柳叶刀集团第二阶段扩张所创办的专科期刊之一，同期创刊的还有（The Lancet Diabetes & Endocrinology）与（The Lancet Global Health）等。
• It is published by Elsevier and continues the Lancet tradition of editorial independence and global reach该刊由（Elsevier）出版，延续柳叶刀的编辑独立与全球视野传统。
• Rob Brierley has served as Editor-in-Chief since the journal's launch in 2016Rob Brierley 自该刊 2016 年创刊起担任主编。
• Its Journal Impact Factor has moved from 18.486 in 2021 to 45.042 in 2022, 38.6 in 2024 and 39.1 in 2025, ranking third among 153 gastroenterology and hepatology journals其期刊影响因子由 2021 年的 18.486 升至 2022 年的 45.042、2024 年的 38.6 与 2025 年的 39.1，在 153 种胃肠病学与肝病学期刊中排名第三。
• Its electronic international standard serial number is 2468-1253, and it is published online only其电子国际标准连续出版物号为 2468-1253，仅以在线形式出版。

Editors

• The Editor-in-Chief is Robert Brierley, generally known as Rob Brierley现任主编为 Robert Brierley，通称 Rob Brierley。
• He studied molecular and cellular biochemistry and clinical pharmacology at the University of Oxford and clinical oncology at the University of Birmingham他于（University of Oxford）学习分子与细胞生物化学及临床药理学，并在（University of Birmingham）学习临床肿瘤学。
• He worked as a technical editor for the Journal of Molecular Biology and helped prepare a series of viral hepatitis textbooks他曾任（Journal of Molecular Biology）的科技编辑，并参与编写一系列病毒性肝炎教科书。
• He joined The Lancet in 2004, worked on The Lancet Infectious Diseases and The Lancet Oncology, became a Deputy Editor in 2012 and took charge of this journal in 2016他 2004 年加入（The Lancet），先后任职于（The Lancet Infectious Diseases）与（The Lancet Oncology），2012 年升任副主编，2016 年起执掌本刊。
• Its editorial office is in London, and the editorial team can be reached at gastrohep@lancet.com其编辑部设于伦敦，编辑团队的联系邮箱为（gastrohep@lancet.com）。
• Its content is stringently edited and peer reviewed to ensure the scientific merit and clinical relevance of its material其内容经过严格编辑与同行评审，以确保材料的科学价值与临床相关性。